MedTrace Logo

A Study of TY-302 in Patients With Advanced Solid Tumors

NCT04433494 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-12-07

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are:

* TY-302
* Tamoxifen

Conditions

Interventions

DRUG

TY-302: capsule, 25mg/50mg ; Tamoxifen: tablet,10mg

TY-302 is taken orally. Tamoxifen is taken orally.

Sponsors & Collaborators

  • TYK Medicines, Inc

    lead INDUSTRY

Principal Investigators

  • Binghe Xu, MD · Chinese Academy of Medical Sciences and Peking Union Medical Colledge

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-07
Primary Completion
2023-05-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04433494 on ClinicalTrials.gov